Early-stage venture firm led by AI practitioners and focused on companies developing industry-changing artificial intelligence.
Founded —
Type Venture capital 3 AIX Ventures Fund III, L.P. 2026-08-21 2026-08-21 — SEC Form D/A offeringUSD250m, soldUSD61.21m remainingUSD188.79m; firstsale2026-06-05,38investors. Offering/sold amounts are not verified final close/AUM.
Fund II 2024-02-13 2024-02-13 $202M Announced second fund size; early-stage AI. Not presented as target, but explicit final-close terminology absent.
Fund I 2022-03-23 2022-03-23 $50M Announced operating fund size; pre-seed/seed. Explicit final close date not disclosed.
SHOW MORE
$1M $500K – $2M Berkeley, California · San Francisco, California $1M $100K – $5M Cambridge, Massachusetts $1M $250K – $3M Chicago, Illinois $1M $500K – $2M New York, New York $1M $500K – $2M San Francisco Bay Area $1M $500K – $2M San Francisco Bay Area $1M $500K – $2M San Francisco, California $1M $500K – $2M Stanford, California $1M $500K – $2M Stanford, California $25K $5K – $50K New York, New York — — – — — — – — — — – —
SHOW MORE
$30M 2025-08-11 Tahoe Therapeutics Amplify Partners , General Catalyst , Mubadala Ventures , Wing Venture Capital , Databricks Ventures , Overlap Holdings , Civilization Ventures , Conviction , AIX Ventures , Krish Ramadurai , Sunil Dhaliwal , Gaurav Garg , Deep Nishar , Elena Viboch $2M 2022-07-25 Ubenwa Radical Ventures , AIX Ventures $100M 2022-05-09 Huggingface Lux Capital , Sequoia Capital , Coatue , Addition , A Capital , SV Angel , Betaworks , AIX Ventures , Kevin Durant , Rich Kleiman , Olivier Pomel $7M Unknown date Atomic AI AIX Ventures $— Unknown date You.com AIX Ventures $— Unknown date Weights & Biases AIX Ventures $— Unknown date TollBit AIX Ventures $— Unknown date Ambience AIX Ventures $— Unknown date Wispr Flow AIX Ventures $— Unknown date Windsurf AIX Ventures $— Unknown date Perplexity AIX Ventures
SHOW MORE
team@apexlogos.ai · 13 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size and fundraising
| Vehicle / vintage | Amount and currency | Date / evidence | Interpretation |
| --- | --- | --- | --- |
| Fund I, launch 2022 | USD 50m | Official announcement dated 2022-03-23 on [fund-news](https://www.aixventures.com/fund-news ) | Announced operating fund size, focused on pre-seed and seed. The wording does not explicitly specify a final-close date. |
| Fund II, announced 2024 | USD 202m | Official announcement 2024-02-13 on [fund-news](https://www.aixventures.com/fund-news ) | Announced second-fund size for early-stage AI, with capacity to lead more rounds. This is not presented as a target; explicit final-close terminology is absent. |
| AIX Ventures Fund III, L.P.; legal entity formed 2025, offering 2026 | USD 250m total offering; USD 61.21m sold; USD 188.79m remaining | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/2094177/000209417726000004/xslFormDX01/primary_doc.xml ), filed/signed 2026-08-21 | Latest-known fundraising evidence located. First sale 2026-06-05; 38 investors. USD 250m is an offering amount/target, not a final closed fund. USD 61.21m is reported securities sold as of the amendment, not AUM or current cash. |
The SEC [original filing index](https://www.sec.gov/Archives/edgar/data/2094177/000209417726000003/0002094177-26-000003-index.htm ) dates the initial Fund III notice to 2026-06-04. No subsequent close announcement was located in a fresh search of Fund III and the official announcements on 2026-10-06. Third-party fund summaries can describe the USD 250m offering as a closed fund; the primary amendment establishes only USD 61.21m sold against the offering, so those summaries are not reliable final-close evidence. SEC notices contain issuer-reported data, not an SEC certification. The amendment names Richard Socher as managing member of the general partner and gives a Newark, California principal-place-of-business address for this fund entity; that does not independently settle the management firm's headquarters. No verified firmwide AUM found. Do not add fund sizes or target amounts and describe the result as AUM.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Fund I | USD 50000000 | 2022-03-23 |
| Fund II | USD 202000000 | 2024-02-13 |
| AIX Ventures Fund III, L.P. | Undisclosed / unverified | 2026-08-21 | SHOW MORE
team@apexlogos.ai · 13 hours ago
Match research 2026-10-06 / AIXVentures / sha256:2983f57ef2c3b2906b77c6eb591d369f50129968ef212032cd38760ecf730d52 / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
Atomic AI's seed year and follow-on attribution need care. An [investor-authored Not Boring article](https://www.notboring.co/p/atomic-ai-unlocking-rna ), **2023-01-25**, dates the USD 7m seed to **2022** and broadly describes the Series A as including seed investors. Its author discloses Not Boring Capital's investment, so this is informed but interested evidence. The company release's specific Series A list omits AIX; record the verified seed participation and the conflicting broad follow-on wording rather than infer AIX's Series A check. The Business Wire release was search-index accessible, but the earlier direct extraction returned an error. A fresh index read on 2026-10-06 confirmed the separate seed and Series A participant lists. [Dealroom](https://app.dealroom.co/companies/atomic_ai ) instead dates the seed to January 2021, conflicting with the investor-authored 2022 history; its asterisk indicates an estimated date. The precise seed date remains unresolved rather than accepting a database placeholder.
The current [official portfolio](https://www.aixventures.com/portfolio ), undated, accessed 2026-10-06, also names **Machina Labs** (AI manufacturing), **Covariant.ai** (robotics), **Profluent Bio** (protein design), **Atmo** (weather prediction), **Parallel Bio** (immunology) and **Chroma** (embedding infrastructure). These are relevant additional deep-tech leads, but this review does not establish their specific AIX rounds. Covariant requires particular care: AIX's launch announcement separately describes Fang Yuan's earlier **Baidu Ventures** investment. Do not attribute that predecessor transaction to AIX simply because Covariant appears in the current portfolio. Perplexity, Weights & Biases and You.com remain verified portfolio claims; company-specific financing detail was not established here. Ordinary workflow products such as Windsurf, TollBit and Ambience should not be indiscriminately relabeled deep tech.
## Neurotech history and adjacent investments
**Wispr is a verified historical neurotechnology company and a verified current AIX portfolio company; AIX's investment during the neurotechnology period remains unverified.** Its [company-authored seed announcement](https://wispr-ai.medium.com/announcing-wisprs-4-6m-seed-round-84a51ee52a15 ), **2021-12-01**, explains wearable EMG capture of intentional muscle signals for human-computer interaction and announces **USD 4.6m seed financing**, co-led by NEA and 8VC. It names **Chris Manning individually**, identifying him as an AIX investment partner; it does not explicitly name the AIX fund as subscriber. EMG measures peripheral muscle activity rather than implanted/direct brain recording. Partner affiliation is not proof of firm capital participation.
The official [AIX Wispr interview](https://www.aixventures.com/fireside-chat-with-tanay-kothari-at-wispr-flow ), undated, accessed 2026-10-06, says the company began with a silent-speech earpiece and pivoted to Flow software in **2024**. Thus current voice dictation is not evidence of a currently operating brain interface. [Wispr's official funding update](https://wisprflow.ai/new-funding ), **2025-11-20**, describes voice-native computing and USD 25m new funding led by Notable with Flight Fund, but does not name AIX in that round.
Wispr's [company-issued PR Newswire release](https://www.prnewswire.com/news-releases/wispr-raises-25m-to-build-its-voice-operating-system-302621858.html ), **2025-11-20**, names AIX among its cumulative investors, reinforcing firm attribution without allocating it to that round. [Forge's secondary-market funding table](https://forgeglobal.com/wispr-flow_stock/ ), undated, accessed 2026-10-06, assigns AIX to **2021-11-30**, **USD 4.62m**, labeled **Series A-2**. This differs from the company's **2021-12-01 USD 4.6m seed** announcement; close versus announcement timing and legal share class versus marketing stage may explain differences, but no primary allocation document was located. Treat Forge as a corroboration lead, not sufficient proof of an AIX fund subscription during the hardware period.
**Ubenwa is verified neuroscience-adjacent exposure**, rather than direct recording or stimulation of neural activity. Its official financing announcement supports neurological-injury screening from infant cries. The [research preprint](https://arxiv.org/abs/2310.08338 ), submitted **2023-10-12**, studies cry-based detection of neonatal brain injury; it provides technical grounding, not investment evidence or proof of regulatory approval. Acoustic inference about neurological health should not be equated with a BCI or neural implant.
**No verified neurotech investment found in the sources checked** with both explicit AIX firm financing attribution and a neurotechnology-era date/round. This is a narrowly stated evidence limit, not a claim that AIX has never invested in neurotech. **Ellipsis Health** is also in AIX's official portfolio, described there as speech-based assessment of stress, depression and anxiety. Its [current site](https://ellipsishealth.com/ ), undated, accessed 2026-10-06, markets an AI care manager. Treat it as adjacent mental-health/voice AI, not direct neural sensing or stimulation. Tahoe/Atomic's biology and Ambience's clinical documentation do not establish direct neurotechnology exposure.
## Conflicts, missing information and later Adex review
- Preserve the exact ID and confirmed Hugging Face/Tahoe firm participation. For Tahoe, review whether the Series A label has independent primary support; the funding release itself says only new funding.
- Add separate fund facts with their dates/status: USD 50m Fund I; USD 202m Fund II as announced sizes; Fund III USD 250m offering versus USD 61.21m sold. Leave final-close date and AUM unresolved. Check for later Fund III amendments before updating a “latest fund” field.
- Current official firmwide checks are USD 1–5m; do not substitute individual Signal ranges. Specific investee checks and fund allocations remain undisclosed.
- Review stale roles. The [official team page](https://www.aixventures.com/team ), undated, accessed 2026-10-06, calls Sara Tatman **Senior EA & Operations**, Ellie Wheeler **Chief Operating Officer**, Richard Socher **Co-Founder & Managing Partner**, Anthony Goldbloom and Christopher Manning **AI Partners**, and Krish Ramadurai/Nick Crance **Partners**. Adex's generic investor labels for Tatman/Wheeler are misleading. Jason McBride, Shaun Johnson, Bianca Caban, Pieter Abbeel, Suchi Saria and Christina Sfakianos are absent from the current displayed roster; absence does not establish departure or end dates. Launch-era names need historical role preservation rather than deletion by inference.
- Headquarters remains uncertain across Adex's San Francisco, Signal's multiple location tags and the Newark fund-entity SEC address. The firm's [LinkedIn profile](https://www.linkedin.com/company/aixventures ), search-index accessible, undated, accessed 2026-10-06, also reports San Francisco; this supports the operating-location claim but does not make the fund-entity address equivalent to headquarters.
- Wispr requires explicit firm/partner and historical/current-technology qualifications. Ask for fund-level financing evidence before adding an unqualified AIX neural-interface investment. Do not add its seed round as an AIX firm participation on the basis of Manning alone.
- Ubenwa is an additional company-confirmed AIX financing absent from the snapshot's named deals. Consider it for later review as neuroscience-adjacent medical AI, preserving the pre-seed date evidence and returning-investor qualification. Atomic AI's seed year has investor-source support but exact seed close date remains missing.
- The portfolio page repeats a generic **2021-07-17** timestamp and web-designer name across many companies; these are CMS artifacts, not reliable investment dates. Do not copy them into transactions.
Research resumed and finalized **2026-10-06**: Signal, official fundraising/FAQ/team/portfolio, SEC Fund III, and the Hugging Face, Tahoe, Ubenwa and Wispr primary announcements were reopened. Wispr's [2022-10-24 USD 10m follow-on announcement](https://wispr-ai.medium.com/press-release-wispr-raises-another-10m-to-build-a-more-natural-way-to-interact-with-technology-5655f4ea3b47 ) names Neo, NEA and 8VC; it adds no explicit AIX firm allocation, so the historical financing caveat remains. All linked sources were accessed **2026-10-06**. Dates above denote publication/filing dates when identifiable; undated pages are explicitly labeled. Official portfolio inclusion verifies a firm claim, not necessarily the precise legal investor vehicle or transaction. This file contains research only; no Adex/database changes were made. SHOW MORE
team@apexlogos.ai · 13 hours ago
Match research 2026-10-06 / AIXVentures / sha256:2983f57ef2c3b2906b77c6eb591d369f50129968ef212032cd38760ecf730d52 / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# AIX Ventures
- **Exact Adex ID:** `AIXVentures`
- **Canonical Adex URL:** https://adex.page/firms/AIXVentures
- **Research date:** 2026-10-06
- **Status:** Complete research; unresolved attribution and disclosure limits documented below.
AIX Ventures is an AI-practitioner-led venture firm. Its current official mandate spans pre-seed through Series A, with later follow-ons. Named, company-confirmed investments include Hugging Face, Atomic AI and Tahoe Therapeutics. Wispr is an important historical neurotechnology lead, but the evidence establishes current AIX portfolio attribution and a partner's individual 2021 financing participation separately; it does not establish which AIX fund financed the original neural-interface work. [Official about page](https://www.aixventures.com/about ), [FAQ](https://www.aixventures.com/faq ), undated, accessed 2026-10-06.
## Starting evidence: Adex and NFX Signal
The existing read-only Adex snapshot, `data/research/_sources/AIXVentures.adex.json`, was retrieved 2026-10-06. It describes early-stage AI investing, lists San Francisco, has no fund-size or check-size figures, and attaches thirteen people. It records Hugging Face's USD 100m financing on 2022-05-09 and Tahoe's USD 30m financing on 2025-08-11, plus undated firm-website portfolio entries for Ambience, Perplexity, TollBit, Weights & Biases, Windsurf, Wispr Flow and You.com. Those round totals are not AIX checks. These are starting claims, independently checked only where noted below.
The [NFX Signal firm page](https://signal.nfx.com/firms/aix-ventures ) was directly readable; it headlines New York and lists multiple additional locations including San Francisco and Berkeley. These tags do not verify headquarters. The directly read [Krish Ramadurai profile](https://signal.nfx.com/investors/krish-ramadurai ) lists AIX partner status, a USD 250k–3m range, a USD 1m sweet spot, and seed/Series A deep-tech and biotechnology rankings. Its nine investment records require Google sign-in in the current public rendering; the saved Adex source preserves a Tahoe August 2025 Signal claim, which could not be freshly read in the public deal list. Signal also lists a concurrent Harmonix partnership. Consequently its personal deal history cannot automatically be assigned to AIX. Intro paths require Google sign-in. A guessed Chris Manning profile URL was inaccessible and supplies no evidence. Both Signal pages are undated, accessed 2026-10-06; their claims are discovery evidence, not independently verified firm policy or transactions.
## Fund size and fundraising
| Vehicle / vintage | Amount and currency | Date / evidence | Interpretation |
| --- | --- | --- | --- |
| Fund I, launch 2022 | USD 50m | Official announcement dated 2022-03-23 on [fund-news](https://www.aixventures.com/fund-news ) | Announced operating fund size, focused on pre-seed and seed. The wording does not explicitly specify a final-close date. |
| Fund II, announced 2024 | USD 202m | Official announcement 2024-02-13 on [fund-news](https://www.aixventures.com/fund-news ) | Announced second-fund size for early-stage AI, with capacity to lead more rounds. This is not presented as a target; explicit final-close terminology is absent. |
| AIX Ventures Fund III, L.P.; legal entity formed 2025, offering 2026 | USD 250m total offering; USD 61.21m sold; USD 188.79m remaining | [SEC Form D/A](https://www.sec.gov/Archives/edgar/data/2094177/000209417726000004/xslFormDX01/primary_doc.xml ), filed/signed 2026-08-21 | Latest-known fundraising evidence located. First sale 2026-06-05; 38 investors. USD 250m is an offering amount/target, not a final closed fund. USD 61.21m is reported securities sold as of the amendment, not AUM or current cash. |
The SEC [original filing index](https://www.sec.gov/Archives/edgar/data/2094177/000209417726000003/0002094177-26-000003-index.htm ) dates the initial Fund III notice to 2026-06-04. No subsequent close announcement was located in a fresh search of Fund III and the official announcements on 2026-10-06. Third-party fund summaries can describe the USD 250m offering as a closed fund; the primary amendment establishes only USD 61.21m sold against the offering, so those summaries are not reliable final-close evidence. SEC notices contain issuer-reported data, not an SEC certification. The amendment names Richard Socher as managing member of the general partner and gives a Newark, California principal-place-of-business address for this fund entity; that does not independently settle the management firm's headquarters. No verified firmwide AUM found. Do not add fund sizes or target amounts and describe the result as AUM.
## Investment stages and checks
The current official [FAQ](https://www.aixventures.com/faq ), undated, accessed 2026-10-06, explicitly supports **pre-seed, seed and Series A**, **USD 1–5m target checks**, leading or co-investing, and reserves for Series A and later follow-ons. AI must already be central to the product. Its areas include NLP, computer vision and robotics, with current interest in future-of-work applications/infrastructure and healthcare/life sciences among broader sectors. The official firm policy takes precedence over Signal's narrower personal range. Historical participation in Hugging Face's Series C does not turn the current initial-investment mandate into general growth-stage investing.
## Named previous deep-tech investments
“Deep tech” here is a research classification based on the underlying technology, not a claim that every AI application meets it. Company round totals below are distinct from AIX's undisclosed checks.
| Company | Technology and classification | Firm attribution / financing evidence |
| --- | --- | --- |
| **Tahoe Therapeutics** | Perturbative single-cell experimental datasets and biological foundation models for drug discovery; strong computational biology/deep-tech rationale. Not established as direct neurotechnology. | [Official company announcement](https://www.tahoebio.ai/news/tahoe-therapeutics-raises-30m ), **2025-08-11**, names AIX among participants in **USD 30m** led by Amplify Partners. The release does not explicitly label the stage; Adex and Signal say Series A, so retain that qualification. |
| **Atomic AI** | Machine learning coupled to structural biology and wet-lab assays to predict RNA structure and develop RNA medicines. [Official technology site](https://atomic.ai/ ), undated, accessed 2026-10-06. | [Company financing release distributed by Business Wire](https://www.businesswire.com/news/home/20230125005256/en/Atomic-AI-Launches-with-35-Million-Series-A-Financing-to-Advance-AI-driven-RNA-Structure-Platform-for-Treating-Undruggable-Diseases ), **2023-01-25**, explicitly names AIX in the **prior USD 7m seed round** led by 8VC. The seed date is unspecified in this primary release. Do not transfer AIX to the headline USD 35m Series A, whose participant list does not name it. |
| **Hugging Face** | Open machine-learning model/dataset infrastructure spanning NLP, computer vision and scientific applications; qualifies as advanced AI infrastructure rather than ordinary SaaS. | [Official Series C announcement](https://huggingface.co/blog/series-c ), **2022-05-09**, names AIX among existing investors supporting the **USD 100m Series C** led by Lux Capital. Confirms the baseline transaction. |
| **Wispr / Wispr Flow** | Historical EMG/silent-speech interface hardware; now voice transcription software. Historical hardware has a stronger deep-tech rationale than the current app alone. | Current AIX portfolio attribution is directly supported by its [homepage](https://www.aixventures.com/ ) and [founder interview](https://www.aixventures.com/fireside-chat-with-tanay-kothari-at-wispr-flow ), undated, accessed 2026-10-06. Exact AIX investment date, vehicle, check and round remain unknown; see neurotech qualification below. |
| **Ubenwa** | Clinically developed acoustic biomarkers and machine learning for infant neurological-injury screening; research-based medical AI, with neuroscience-adjacent applications. | [Official pre-seed announcement](https://www.ubenwa.ai/news/ubenwa-raises-pre-seed ), undated, accessed 2026-10-06, explicitly calls AIX a **returning investor** in a **USD 2.5m pre-seed** led by Radical Ventures. Contemporary [TechCrunch reporting](https://techcrunch.com/2022/07/25/can-a-babys-cry-identify-neurological-disorders-ubenwa-says-yes/ ), **2022-07-25**, corroborates amount, stage and AIX participation. Earlier AIX financing date/amount remain undisclosed. | SHOW MORE
team@apexlogos.ai · 23 days ago
MATCH 
Huggingface$100M · 2022-05-09
Amplify Partners
Tahoe Therapeutics$30M · 2025-08-11
Deep Nishar
Elena Viboch
Gaurav Garg
General Catalyst
Kevin Durant
Lux Capital
Olivier Pomel
Radical Ventures
Ubenwa$2M · 2022-07-25
Rich Kleiman
Sunil Dhaliwal
Wing Venture Capital
Atomic AI
You.com
Weights & Biases
TollBit
Ambience